Werner Lanthaler, Evotec CEO

Evotec’s CNS deal with Bris­tol My­ers gets $50M in­fu­sion and eight-year ex­ten­sion

Bris­tol My­ers Squibb is up­ping the ante on its neu­rode­gen­er­a­tion part­ner­ship with Ger­man biotech Evotec. The Big Phar­ma will dole out $50 mil­lion up­front to ex­pand the sev­en-year col­lab­o­ra­tion by an­oth­er eight years.

Orig­i­nal­ly inked with Cel­gene, the part­ner­ship will now bal­loon to a po­ten­tial $4 bil­lion as the part­ners look at pre­ci­sion med­i­cines across a va­ri­ety of modal­i­ties. The first pro­gram in-li­censed by BMS, EVT8683 for $20 mil­lion in 2021, is a small mol­e­cule in a Phase I study. Low dou­ble-dig­it tiered roy­al­ties are al­so on the ta­ble.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.